Book a Meeting

Anti-Mucin 5AC Antibody, Non-Fucosylated (BioBet-1470ZP) (CAT#: BioBet-1470ZP) Datasheet

Target
Mucin 5AC
Isotype
IgG
Description
Anti-Mucin 5AC Antibody, Non-Fucosylated (BioBet-1470ZP) is a chimeric monoclonal IgG antibody against Mucin 5AC. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Myotubular Myopathy
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Mucin 5AC antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
MUC5AC
Full Name
mucin 5AC, oligomeric mucus/gel-forming
Alternative Names
MUC5AC; mucin 5AC, oligomeric mucus/gel-forming; TBM; leB; MUC5; mucin-5AC; gastric mucin; tracheobronchial mucin; major airway glycoprotein; lewis B blood group antigen; mucin-5 subtype AC, tracheobronchial; mucin 5AC, oligomeric mucus/gel-forming pseudogene; mucin 5, subtypes A and C, tracheobronchial/gastric;
Gene ID
4586
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with MUC5AC include Barrett Esophagus and Biliary Papillomatosis.
Related Pathways
Its related pathways are Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) and Metabolism of proteins.
Function
The glycoproteins that form a gel in the epithelium of the stomach and respiratory tract protect the mucosa from infection and chemical damage by binding to inhaled microorganisms and particles. These microorganisms and particles are then removed by the hair ciliary system. Interacts with Helicobacter pylori in gastric epithelium, Barrett's esophagus and duodenal metaplasia.
Post-translational modifications
C-, O- and N-glycosylated. O-glycosylated on the Thr-/Ser-rich tandem repeats. C-mannosylation in the Cys-rich subdomains may be required for proper folding of these regions and for export from the endoplasmic reticulum during biosynthesis. Proteolytic cleavage in the C-terminal is initiated early in the secretory pathway and does not involve a serine protease. The extent of cleavage is increased in the acidic parts of the secretory pathway. Cleavage generates a reactive group which could link the protein to a primary amide.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1470ZP
Host
Chimeric
Species Reactivity
Human
Description
This polypeptides comprising myotubularin 1 (MTMI) polypeptides and an internalising moiety which can be a monoclonal antibody 3E10. It can be used as a further therapeutic agent of treating Myotubular Myopathy.
Antibody Indication
Myotubular Myopathy

Myotubular Myopathy

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.